Gilead Sciences, Inc. is a prominent biopharmaceutical company that discovers, develops, and commercializes therapeutics for life-threatening diseases. The company's business model centers on the research and development of innovative medicines, primarily in the fields of virology, oncology, and liver disease. Gilead generates the vast majority of its revenue from product sales, with its HIV franchise serving as the cornerstone of its business. In 2023, the company reported total revenues of approximately $27.1 billion. The HIV segment, featuring blockbuster drugs like Biktarvy and Descovy, accounted for over $18 billion in sales, representing the largest portion of its revenue.
Beyond HIV, Gilead has a significant presence in the treatment of liver diseases, including hepatitis C (HCV) and hepatitis B (HBV), with products such as Epclusa, Harvoni, and Vemlidy. The company also developed Veklury (remdesivir), an antiviral treatment for COVID-19, which contributed substantially to revenues during the pandemic but has seen declining sales as hospitalization rates have normalized. In recent years, Gilead has strategically expanded its oncology and cell therapy portfolios through acquisitions and internal development. Its oncology segment includes Trodelvy, an antibody-drug conjugate for breast cancer, and CAR-T cell therapies like Yescarta and Tecartus, developed by its subsidiary Kite Pharma.
Geographically, Gilead operates worldwide, with the United States being its largest market, followed by Europe and other international regions. The company's competitive position is anchored by its dominant market share in HIV treatments and its pioneering role in curative therapies for hepatitis C. Gilead continues to invest heavily in research and development to diversify its pipeline, particularly in oncology and inflammation, to sustain long-term growth and reduce its reliance on its core antiviral franchises.
